AstraZeneca COPD drug data lifts Citi sales outlook sharply
Citi analysts say AstraZeneca’s blowout clinical data for tozorakimab supports sales expectations sharply above current consensus estimates, according to a research note.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.